{
    "id": 1169,
    "fullName": "KRAS Q61X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS Q61X indicates any KRAS missense mutation that results in replacement of the glutamine (Q) at amino acid 61 by a different amino acid. KRAS codon 61 mutations often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 28666118, PMID: 22589270, PMID: 26902995).",
            "references": [
                {
                    "id": 2097,
                    "pubMedId": 22589270,
                    "title": "A comprehensive survey of Ras mutations in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22589270"
                },
                {
                    "id": 9843,
                    "pubMedId": 28666118,
                    "title": "RAS Proteins and Their Regulators in Human Disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28666118"
                },
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                },
                {
                    "id": 9846,
                    "pubMedId": 26902995,
                    "title": "The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26902995"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "Q61X",
    "createDate": "07/27/2014",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 157389,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25227341_25227343",
        "cDna": "c.181_183",
        "protein": "p.Q61",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16006,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of cancer cell lines harboring KRAS Q61X (H,K,L) mutations in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1194,
                "profileName": "KRAS Q61X"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17101,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1194,
                "profileName": "KRAS Q61X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17115,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1194,
                "profileName": "KRAS Q61X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3383,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).",
            "molecularProfile": {
                "id": 13307,
                "profileName": "KRAS Q61X PIK3CA mut"
            },
            "therapy": {
                "id": 1121,
                "therapyName": "Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1194,
            "profileName": "KRAS Q61X",
            "profileTreatmentApproaches": [
                {
                    "id": 15817,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15815,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15814,
                    "name": "AZD4785",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15816,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15819,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15813,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS Q61X"
                },
                {
                    "id": 15818,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS Q61X"
                }
            ]
        },
        {
            "id": 13307,
            "profileName": "KRAS Q61X PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157390,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25227341_25227343",
            "cDna": "c.181_183",
            "protein": "p.Q61",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157392,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25227341_25227343",
            "cDna": "c.181_183",
            "protein": "p.Q61",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157388,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25227341_25227343",
            "cDna": "c.181_183",
            "protein": "p.Q61",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157391,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25227341_25227343",
            "cDna": "c.181_183",
            "protein": "p.Q61",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157389,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25227341_25227343",
            "cDna": "c.181_183",
            "protein": "p.Q61",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}